TMS earns its first clearance in PTSD
STUDY: Unpublished trial described in Frontier Psychiatrist and Press Release
STUDY TYPE: Randomized, sham-controlled trial
FUNDING: Wave Neuroscience (device manufacturer)
On June 3, 2026, the FDA cleared Magnetic EEG Resonance Therapy (MeRT) for the adjunctive treatment of PTSD. The name is new but the treatment is familiar. It is transcranial magnetic stimulation (TMS) that uses EEG to direct the magnet, personalizing the treatment based on brain activity much as Stanford Neuromodulation Therapy (SNT or SAINT TMS) does with PET-scan guided neuromodulation.
The clearance was based on a multi-site, double-blind, sham-controlled trial of 156 adults. It follows the FDA-approval last month of Modius Spero, an at-home neuromodulation device for PTSD.
MeRT TMS is already available, and you can find providers on the Wave Neuroscience website.
—Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report
